| Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 09/12 16:01 | businesswire.com |
| Xencor: Vudalimab Development Along With Hidden Gem Candidate | 09/12 08:16 | seekingalpha.com |
| Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains? | 09/12 05:55 | zacks.com |
| Xencor Stock Gains 23% on Encouraging Pipeline Advancements | 09/10 13:25 | zacks.com |
| Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs | 09/09 07:31 | businesswire.com |
| Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates | 08/05 18:15 | zacks.com |
| Xencor Regains CD20 x CD3 Bispecific T-Cell Engager | 06/13 08:01 | businesswire.com |
| Xencor Reports First Quarter 2024 Financial Results | 05/09 16:09 | businesswire.com |
| Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? | 05/06 11:01 | zacks.com |
| Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last? | 05/02 04:35 | zacks.com |